Replimune Group (7R8) Price & Analysis

Compare

0 Followers

7R8 Stock Chart & Stats

€7.25

-€0.80(-7.02%)

At close: Jan 08 4:00 PM EST

€7.25

-€0.80(-7.02%)

Day’s Range― - ―

52-Week Range€2.30 - €15.00

Previous CloseN/A

Volume0.00

Average Volume (3M)71.00

Market Cap

$573.47M

Enterprise ValueN/A

Total Cash (Recent Filing)$323.64M

Total Debt (Recent Filing)$29.12M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

May 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.78

Shares Outstanding78,055,850

10 Day Avg. Volume170

30 Day Avg. Volume71

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)1.89

Price to Sales (P/S)0.00

P/FCF Ratio-3.95

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$9.66

Price Target Upside33.18% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessIGNYTE trial results support approval with an objective response rate of 33.6%, which is significantly higher than expected with anti-PD1 agents alone.

Financial StrengthReplimune ended the financial quarter with a strong cash position, providing an operational runway that extends into several key data catalysts and a potential market launch.

Regulatory ProgressThe FDA has accepted the resubmission of the Biologics License Application for RP1 + Opdivo for review, indicating progress towards potential approval.

Bears Say

Regulatory ChallengesThe regulatory process has been volatile for the product, and it may take time to get comfortable with the back and forth with the Agency.

Skepticism On Trial DataRegulators seem to remain skeptical about the clinical data from the single-arm IGNYTE trial as the basis for accelerated approval.

Uncertain Approval PathThere is a prolonged path to approval for RP1, as Replimune will likely have to run another trial to garner approval in the U.S.

Replimune Group News

Replimune reports Q2 EPS (90c), consensus (79c)

“After a collaborative dialogue and productive engagement with the FDA we are encouraged by the acceptance of our...

3d ago

REPL

Replimune upgraded to Market Perform from Underperform at BMO Capital

BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of...

6d ago

REPL

Replimune upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted...

13d ago

REPL

Genelux price target raised to $20 from $10 at Maxim

Maxim raised the firm’s price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating...

19d ago

GNLX

REPL

Piper upgrades Replimune to Overweight on ‘very pleasant surprise’

Piper Sandler upgraded Replimune (REPL) to Overweight from Neutral with a price target of $13, up from $8....

20d ago

REPL

Replimune upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler analyst Allison Bratzel upgraded Replimune (REPL) to Overweight from Neutral with a price target of $13,...

20d ago

REPL

Replimune upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Replimune (REPL) to Neutral from Underweight with an $11 price target Published first on TheFly –...

20d ago

REPL

Replimune upgraded to Neutral at JPMorgan after BLA resubmission accepted

As previously reported, JPMorgan upgraded Replimune (REPL) to Neutral from Underweight with an $11 price target after the...

20d ago

REPL

Midday Fly By: AWS hit by outage, Kering sells beauty unit

The major averages were broadly higher near noon as markets opened with a cautiously optimistic tone amid strong...

20d ago

Leerink upgrades Replimune on renewed confidence in RP1

Leerink analyst Jonathan Chang upgraded Replimune (REPL) to Outperform from Market Perform with a price target of $13,...

20d ago

REPL

Replimune Group Reports Increased Losses Amid R&D Expansion

Replimune Group ( ($REPL) ) has released its Q2 earnings. Here is a breakdown of the information Replimune...

2d ago

REPL

Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group and keeping the price target...

3d ago

REPL

Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Study Overview: Replimune Group is conducting a...

13d ago

REPL

Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a Phase 2,...

13d ago

REPL

7R8 FAQ

What was Replimune Group Inc’s price range in the past 12 months?

Replimune Group Inc lowest stock price was €2.30 and its highest was €15.00 in the past 12 months.

What is Replimune Group Inc’s market cap?

Replimune Group Inc’s market cap is $573.47M.

When is Replimune Group Inc’s upcoming earnings report date?

Replimune Group Inc’s upcoming earnings report date is May 14, 2026 which is in 186 days.

How were Replimune Group Inc’s earnings last quarter?

Replimune Group Inc released its earnings results on Nov 06, 2025. The company reported -€0.778 earnings per share for the quarter, missing the consensus estimate of -€0.64 by -€0.138.

Is Replimune Group Inc overvalued?

According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Replimune Group Inc pay dividends?

Replimune Group Inc does not currently pay dividends.

What is Replimune Group Inc’s EPS estimate?

Replimune Group Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Replimune Group Inc have?

Replimune Group Inc has 78,055,850 shares outstanding.

What happened to Replimune Group Inc’s price movement after its last earnings report?

Replimune Group Inc reported an EPS of -€0.778 in its last earnings report, missing expectations of -€0.64. Following the earnings report the stock price went down -4.605%.

Which hedge fund is a major shareholder of Replimune Group Inc?

Currently, no hedge funds are holding shares in DE:7R8

Replimune Group Stock Smart Score

Underperform

Fundamentals

Return on Equity

-96.24%

Trailing 12-Months

Asset Growth

-21.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune Group (7R8) Earnings & Revenues

Historic Earnings Reports

7R8 Stock 12 Month Forecast

Average Price Target

€9.66

▲(33.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","16":"€16","4.75":"€4.75","8.5":"€8.5","12.25":"€12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.61590432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€15.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.6558341712,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€9.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.60265072,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.6,9.139684947692308,9.679369895384616,10.219054843076924,10.75873979076923,11.298424738461538,11.838109686153846,12.377794633846154,12.917479581538462,13.45716452923077,13.996849476923078,14.536534424615386,15.076219372307694,{"y":15.61590432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.6,8.68121801316923,8.762436026338461,8.843654039507692,8.924872052676923,9.006090065846154,9.087308079015385,9.168526092184615,9.249744105353846,9.330962118523077,9.412180131692308,9.493398144861539,9.57461615803077,{"y":9.6558341712,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.6,8.13866544,7.6773308799999995,7.2159963199999995,6.754661759999999,6.2933272,5.831992639999999,5.37065808,4.909323519999999,4.44798896,3.9866544,3.52531984,3.06398528,{"y":2.60265072,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.05,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >